Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.38 |
| ▸ | LTK | P29376 | 2/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452490 | 0.75 | ABCG2 (0.36) | DYRK1ANTRK1NTRK2CLK4LTK | |
| SCHEMBL12483324 | 0.75 | CCR1 (0.48) | ALDH1A1NOS1ABCG2CYP2A6KDM4E | |
| SCHEMBL22400521 | 0.75 | MEN1 (0.37) | DYRK1ANTRK1NTRK2CLK4LTK | |
| SCHEMBL10652292 | 0.75 | MAP4K4 (0.36) | DYRK1ANTRK1NTRK2CLK4LTK | |
| SCHEMBL4486974 | 0.75 | ABCG2 (0.39) | DYRK1ANTRK1NTRK2CLK4LTK | |
| SCHEMBL24565560 | 0.75 | ABCG2 (0.34) | DYRK1ANTRK1NTRK2CLK4LTK | |
| SCHEMBL25054255 | 0.75 | CYP2A6 (0.55) | DYRK1ANTRK1NTRK2CLK4LTK | |
| SCHEMBL21355721 | 0.73 | KDM4E (0.45) | PDGFRBABCG2ADORA2AKDM1AKDM4E | |
| SCHEMBL4508078 | 0.72 | PSMD14 (0.45) | CHEK1LCKKDM4ESMN1; SMN2 | |
| SCHEMBL26199744 | 0.71 | CYP2A6 (0.35) | ABCG2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021063735-A1 | NEW BICYCLIC PYRIDINE DERIVATIVES | BASF SE (DE) | 2021-04-08 | — | — | WO | disclosed |
| US-9126178-B2 | Heat-expandable microspheres and a method of making heat-expandable microspheres and application thereof | MATSUMOTO YUSHI-SEIYAKU CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2529830-A2 | Heat-expandable microspheres and a method of making heat-expandable microspheres and application thereof | MATSUMOTO YUSHI-SEIYAKU CO., LTD. (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2441814-A1 | HEAT-EXPANDABLE MICROSPHERE, METHOD FOR PRODUCING SAME AND USE OF SAME | Matsumoto Yushi-Seiyaku Co., Ltd. (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120064347-A1 | HEAT-EXPANDABLE MICROSPHERES AND A METHOD OF MAKING HEAT-EXPANDABLE MICROSPHERES AND APPLICATION THEREOF | MATSUMOTO YUSHI-SEIYAKU CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-03-15 | — | — | US | disclosed |
| US-8076350-B2 | 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| CN-101568541-A | Spirocyclic azaadamantane derivatives and methods of use | ABBOTT LAB (US) | 2009-10-28 | — | — | CN | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | DYRK1A 3066/4885NTRK1 1989/4885NTRK2 2816/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | DYRK1A 2871/4885NTRK1 2175/4885NTRK2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.